We serve 1-(2-chloroethoxy)-2-methoxyethane CAS:52808-36-3 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name: 1-(2-chloroethoxy)-2-methoxyethane
CAS.NO: 52808-36-3
Molecular Formula: ：C5H11ClO2
Molecular Weight: 138.59300
Synonyms:
2-(2-Methoxyethoxy)ethyl chloride
2-chloro-1-(2-methoxyethoxy)ethane
Ethane,1-(2-chloroethoxy)-2-methoxy
1-Chloro-2-(2-methoxyethoxy)ethane
Physical and Chemical Properties:
Density: 1.025 g / mL at 25 ° C (lit.)
Boiling point: 156ºC at 760mmHg
Melting point:/
Flash point: 44.8ºC
Refractive index: n20 / D 1.41(lit.)
Specification:
Appearance: White crystalline powder
Purity:≥98.0%
Water Content :≤0.5%
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: For pharmaceutical intermediates.
Contact us for information like 1-(2-chloroethoxy)-2-methoxyethane chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1-Chloro-2-(2-methoxyethoxy)ethane physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethane,1-(2-chloroethoxy)-2-methoxy Use and application,1-(2-chloroethoxy)-2-methoxyethane technical grade,usp/ep/jp grade.
Related News: Major global airports, including London Heathrow, are monitoring people arriving from China for signs of illness.2,5-Dichlorothiophene manufacturer Matthew Cheung, Hong Kong’s No. 2 official, appealed to medical workers to reconsider. “At this critical moment, I believe the general public would count on medical personnel to fight against the epidemic together, in the spirit of professionalism,” he wrote in a blog post on Sunday.Methyl Bromopyruvate supplier As of Friday, the virus had claimed the lives of more than 250 people in mainland China.2-Ethylaniline vendor “This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment,” Mankind Pharma Director of Marketing Sanjay Koul said in a statement.The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.
